Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia

被引：0
|
作者：
Fathi, Amir Tahmasb
Arevalo, Mabel
Gutierrez, Sonia
Molero, Antonieta
Sacilotto, Natalia
Limon, Ana E.
Faller, Douglas V.
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[2] Oryzon Genom, Barcelona, Spain
[3] 69 Parkton Rd, Boston, MA USA
[4] Oryzon Genom, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7075
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Frida Study: An Option for Mutated FLT3 Relapsed/Refractory Acute Myeloid Leukemia Patients with a Novel Iadademstat and Gilteritinib Combination Therapy
    Fathi, Amir T.
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana
    Faller, Douglas, V
    BLOOD, 2022, 140 : 11755 - 11756
  • [2] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [3] Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study
    Fathi, Amir T.
    Braun, Theodore P.
    Ambinder, Alexander Joseph
    Borthakur, Gautam
    Redner, Robert L.
    Arevalo, Mabel
    Gutierrez, Sonia
    Limon, Ana
    Faller, Douglas V.
    BLOOD, 2023, 142
  • [4] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Li, Huang
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BLOOD, 2023, 142
  • [5] Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
    Numan, Yazan
    Abdel Rahman, Zaid
    Grenet, Justin
    Boisclair, Stephanie
    Bewersdorf, Jan Philipp
    Collins, Cailin
    Barth, Dylan
    Fraga, Martina
    Bixby, Dale L.
    Zeidan, Amer M.
    Yilmaz, Musa
    Desai, Pankil
    Mannis, Gabriel
    Deutsch, Yehuda E.
    Abaza, Yasmin
    Dinner, Shira
    Frankfurt, Olga
    Litzow, Mark
    Al-Kali, Aref
    Foran, James M.
    Sproat, Lisa Z.
    Jovanovic, Borko
    Daver, Naval
    Perl, Alexander E.
    Altman, Jessica K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 322 - 328
  • [6] Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel Lynn
    Morrissette, Jennifer J. D.
    Lieberman, David B.
    Watt, Christopher
    Schwartz, Gregory W.
    Faryabi, Robert B.
    Ferng, Timothy T.
    Shah, Neil P.
    Smith, Catherine C.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD, 2017, 130
  • [7] Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3Mutated Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark R.
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary J.
    Bradley, Terrence
    Tiu, Ramon V.
    Naqvi, Kiran
    Dail, Monique
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    BLOOD, 2021, 138
  • [8] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [9] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [10] Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation
    Ballesta-Lopez, Octavio
    Solana-Altabella, Antonio
    Megias-Vericat, Juan Eduardo
    Martinez-Cuadron, David
    Montesinos, Pau
    FUTURE ONCOLOGY, 2020, 17 (02) : 215 - 228
12345